AstraZeneca’s immunotherapy drug wins key lung cancer approval – Nasdaq
Nasdaq |
AstraZeneca's immunotherapy drug wins key lung cancer approval
Nasdaq AstraZeneca still hopes to catch up in the advanced lung cancer market too, by combining Imfinzi with another immunotherapy drug called tremelimumab. Initial results from a clinical trial testing this combination proved disappointing last July, but the … Immunotherapy Drug Wins Key Lung Cancer OK | Newsmax.com Astrazeneca shares bounce back after cancer drug approval |
